title: Better response with conjugate vaccine than with polysaccaride vaccine 12 months after rituximab treatment in lymphoma patients.
authors.forename: Magnus
authors.initials: M
authors.lastname: Svensson
authors.forename: Ulrika
authors.initials: U
authors.lastname: Dahlin
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
mesh_terms: D000368:Aged; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology* / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016667:Bacterial Capsules / Q000276:immunology*; D003131:Combined Modality Therapy; D005260:Female; D018073:Haemophilus Vaccines / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000276:immunology*; D011135:Polysaccharides, Bacterial; D000069283:Rituximab; D013296:Streptococcus pneumoniae / Q000276:immunology; D013997:Time Factors; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000276:immunology
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; C570267:Act-Hib vaccine; D000907:Antibodies, Bacterial; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018073:Haemophilus Vaccines; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; D000069283:Rituximab